Clinical Trials Browser

INDUSTRY × Brain Neoplasms × Imatinib Mesylate × Clear all

NCT00171938 2017-02-24

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Phase 2 Terminated

Brain Neoplasms, Glioblastoma

NCT00154375 2011-04-26

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Phase 3 Completed

240 enrolled 8 charts

Adenocarcinoma, Astrocytoma, Brain Neoplasms, Glioblastoma